Hepatocellular Carcinoma — Clinical Case

DCE Long Case

Patient profile

Mr M is a 62-year-old man with chronic hepatitis C cirrhosis who achieved a sustained virological response (SVR) after direct-acting antiviral therapy 2 years ago. He has been undergoing six-monthly HCC surveillance. His latest surveillance ultrasound detected a new liver lesion, and further imaging has confirmed a hepatocellular carcinoma. He has been referred to the hepatology multidisciplinary team for management. [1]

Presenting concern: Mr M has been entirely asymptomatic. His HCC was detected on routine six-monthly surveillance ultrasound, which showed a new 4.2 cm hypoechoic lesion in segment 6. His AFP had risen from a baseline of 12 to 180 ng/mL. A multiphase MRI confirmed a LI-RADS 5 lesion. He feels well, has no abdominal pain, no weight loss, and no symptoms of hepatic decompensation. He was referred for staging and treatment planning. [1]

Past medical history: Chronic hepatitis C (genotype 1b), acquired from a blood transfusion in 1985. He was treated with sofosbuvir-velpatasvir in 2023 and achieved SVR at 12 weeks. Cirrhosis was diagnosed on FibroScan (14.8 kPa) in 2020. Type 2 diabetes (diagnosed 2015, on metformin and empagliflozin). Hypertension (on perindopril 5 mg and amlodipine 5 mg). Dyslipidaemia (on atorvastatin 20 mg). He had an upper GI endoscopy 18 months ago showing small oesophageal varices (no previous bleed). [1]

Medications: Metformin 1000 mg twice daily, empagliflozin 10 mg daily, perindopril 5 mg daily, amlodipine 5 mg daily, atorvastatin 20 mg nocte. No over-the-counter or herbal medications. He does not drink alcohol (stopped in 2020 when cirrhosis was diagnosed; previously 30 to 40 grams per day for 20 years). [1]

Family history: Father died of liver cancer at 68 (details unclear; may have had hepatitis B). Mother with type 2 diabetes. No known family history of hereditary liver disease. [1]

Social: Married, two adult children. Retired schoolteacher. Non-smoker. Minimal alcohol since 2020. He is anxious about the cancer diagnosis and the possibility of surgery. [1]

Examination:

• Well-appearing, no cachexia. ECOG 0.
• Sclerae mildly icteric. Several spider naevi on the upper chest. Palmar erythema.
• Blood pressure 138/82. Pulse 68, regular.
• Abdomen: a firm, irregular liver edge palpable 3 cm below the costal margin. Spleen tip palpable. No ascites. No caput medusae.
• No peripheral oedema. No asterixis. Alert and oriented. [1]

Investigations:

• Bilirubin 18 micromol/L, ALT 42 U/L, ALP 110 U/L, albumin 36 g/L, INR 1.1, platelets 95 x 10^9/L.
• AFP 180 ng/mL (baseline 12).
• HCV RNA undetectable (SVR confirmed). HBsAg negative.
• Child-Pugh score: 5 (Child-Pugh A).
• FibroScan: 14.8 kPa (cirrhosis).
• Multiphase MRI: 4.2 cm lesion in segment 6 with arterial phase hyperenhancement, portal venous washout, and an enhancing capsule. LI-RADS 5. No vascular invasion. No extrahepatic spread. Portal vein patent.
• Upper GI endoscopy (18 months ago): small oesophageal varices, no high-risk stigmata. [1]

Candidate's opening statement (SASPOP)

"This is Mr M, a 62-year-old retired schoolteacher presenting with an asymptomatic hepatocellular carcinoma detected on six-monthly surveillance in his HCV cirrhosis (post-SVR). The multiphase MRI shows a single 4.2 cm LI-RADS 5 lesion in segment 6 with arterial phase hyperenhancement, washout and a capsule — diagnostic of HCC without biopsy. There is no vascular invasion or extrahepatic spread, and the portal vein is patent. His liver function is Child-Pugh A (score 5) and his ECOG is 0, placing him at BCLC stage A — the curative treatment stage. However, his platelet count of 95 and small varices suggest clinically significant portal hypertension, which is the critical determinant of whether resection is safe or whether transplant or ablation is preferred. His main problems are the HCC needing curative therapy; the cirrhosis with portal hypertension; the persistence of cirrhosis despite his HCV cure; his type 2 diabetes and hypertension; his small oesophageal varices needing primary prophylaxis; and the psychosocial impact of a cancer diagnosis. My priorities are to stage him with the BCLC system, assess his portal pressure to determine the optimal curative modality, refer him urgently to the multidisciplinary team for a resection-versus-ablation-versus-transplant decision, start a non-selective beta-blocker for variceal prophylaxis, and ensure lifelong surveillance." [1]

Structured problem list (numbered, prioritised)

1. BCLC A hepatocellular carcinoma (4.2 cm, LI-RADS 5) — the central problem; needs curative therapy.
2. Cirrhosis with clinically significant portal hypertension — complicates resection; needs portal pressure assessment and variceal prophylaxis.
3. Chronic hepatitis C (post-SVR) with persistent cirrhosis — surveillance continues for life.
4. Small oesophageal varices — need primary prophylaxis.
5. Type 2 diabetes, hypertension, dyslipidaemia — metabolic comorbidities to optimise before surgery.
6. Psychosocial impact — a new cancer diagnosis on top of chronic liver disease; anxiety about surgery. [1]

Integrated management plan

Step 1 — Confirm the diagnosis and staging: [1]

The diagnosis of HCC is confirmed by the LI-RADS 5 imaging — a biopsy is NOT needed in a cirrhotic liver where the imaging features (arterial phase hyperenhancement, washout, capsule) are pathognomonic [2]. Biopsy carries a 1 to 3 percent risk of tumour seeding and is reserved for non-cirrhotic livers, atypical lesions, or when histology would change management.

His BCLC stage is A (early): single tumour, Child-Pugh A, ECOG 0, no vascular invasion, no extrahepatic spread. This is the curative treatment stage [2][1].

Step 2 — Assess the portal pressure to determine the curative modality: [1]

The key decision between resection, ablation, and transplant hinges on the portal pressure. His thrombocytopenia (platelets 95) and small varices suggest clinically significant portal hypertension (CSPH). I would arrange a hepatic venous pressure gradient (HVPG) measurement if available: [1]

• If HVPG is under 10 mmHg (no CSPH): surgical resection is first-line. Five-year survival is 50 to 70 percent. The patient has preserved liver function (Child-Pugh A) and can tolerate the loss of functional liver volume [2].
• If HVPG is above 10 mmHg (CSPH confirmed): resection carries a high risk of post-hepatectomy liver failure and decompensation. The preferred options are liver transplant (he is within Milan criteria: single lesion under 5 cm, no vascular invasion, no extrahepatic spread — five-year survival around 70 percent, recurrence under 15 percent) or thermal ablation (RFA or MWA, though for a 4.2 cm lesion ablation is less reliably complete than for sub-3 cm lesions) [2][1].

I would refer him urgently to the multidisciplinary team (hepatobiliary surgery, interventional radiology, transplant surgery, hepatology, medical oncology) for this decision. If transplant is selected, I would list him and consider bridging therapy (TACE or ablation) while awaiting a donor organ to prevent tumour progression beyond Milan criteria. [1]

Step 3 — Portal hypertension management: [1]

Start a non-selective beta-blocker (carvedilol 6.25 mg daily, titrated to heart rate and blood pressure) for primary prophylaxis of variceal bleeding, given his small varices and platelet count under 150 [2]. Repeat the upper GI endoscopy in 1 to 2 years to monitor the varices.

Step 4 — Management of the underlying liver disease: [1]

His HCV is cured (SVR confirmed), but the cirrhosis persists and so does his HCC risk — approximately 0.5 to 1 percent per year post-SVR [1]. Surveillance continues for life. I would optimise his diabetes (HbA1c target, consider GLP-1 agonist if needed), blood pressure, and lipids. I would assess his nutritional status — sarcopenia is common in cirrhosis and worsens surgical outcomes; I would involve a dietitian.

Step 5 — Comorbidity optimisation before any surgical intervention: [1]

Assess cardiovascular risk (diabetes, hypertension, dyslipidaemia, age 62) with an ECG and consider a cardiology assessment before resection or transplant. Optimise glycaemic control. Ensure his medications are reviewed for perioperative management (metformin held perioperatively, empagliflozin held 3 days before surgery due to euglycaemic DKA risk). [1]

Step 6 — Lifelong surveillance: [1]

After curative treatment, surveillance continues with six-monthly ultrasound plus AFP for life — the cirrhotic liver can produce new tumours, and if he receives a transplant, he needs recurrence surveillance (chest CT, liver imaging, AFP) and graft monitoring. [1]

Step 7 — Communication and psychosocial support: [1]

I would explain the diagnosis in plain language: his surveillance programme detected the cancer early, which is exactly what it was designed to do, and the cancer is at a curable stage. I would explain the three curative options and why the portal pressure assessment matters. I would be honest about the transplant pathway — waiting list times, living donor options, lifelong immunosuppression. I would involve his family, his GP, the transplant coordinator, the dietitian, the social worker, and the hepatology nurse specialist, and offer referral to a patient support group. [1]

Probing questions the examiner would ask

Q: How do you decide between resection, ablation, and transplant for this BCLC A patient? [1]

A: "The decision hinges on the tumour characteristics, the liver function, and critically the portal pressure. He has a single 4.2 cm tumour, Child-Pugh A function, and BCLC A staging — all curative options are on the table. The decisive factor is whether he has clinically significant portal hypertension (CSPH). His platelets of 95 and small varices suggest CSPH, which I would confirm with an HVPG. If the HVPG is under 10 mmHg, surgical resection is first-line — five-year survival is 50 to 70 percent. If the HVPG is above 10 mmHg, resection carries a high risk of post-hepatectomy liver failure, and transplant (he is within Milan criteria) or ablation becomes the preferred option. For a 4.2 cm lesion, ablation is less reliable than for sub-3 cm lesions, so if CSPH is confirmed, transplant is the strongest option [2]."

Q: What are the Milan criteria, and why do they matter for transplant? [1]

A: "The Milan criteria define the tumour burden within which liver transplant achieves an acceptable outcome: a single tumour under 5 cm, or up to 3 tumours each under 3 cm, with no macrovascular invasion and no extrahepatic spread. Within these criteria, five-year post-transplant survival is around 70 percent with recurrence under 15 percent. This patient is within Milan criteria (single 4.2 cm lesion, no vascular invasion, no extrahepatic spread). The criteria are an ethical allocation framework — they identify the tumour burden below which transplant outcomes justify the use of a scarce donor organ. Outside the criteria, the recurrence rate is prohibitive [2][1]."

Q: Why was a biopsy not needed, and when would you biopsy a liver lesion? [1]

A: "In a cirrhotic liver, a LI-RADS 5 lesion is diagnostic of HCC non-invasively — the triad of arterial phase hyperenhancement, portal venous washout, and an enhancing capsule, in a lesion of sufficient size, is pathognomonic [2]. Biopsy carries a 1 to 3 percent risk of tumour seeding along the needle track and is avoided when imaging suffices. I would biopsy in three situations: a non-cirrhotic liver where the imaging criteria are less reliable; an atypical lesion that does not meet full LI-RADS 5 criteria (LR-4 or LR-M, suggesting a malignant lesion not typical of HCC); or when the histological diagnosis would change management — for example, distinguishing HCC from an intrahepatic cholangiocarcinoma."

Q: Why does he still have HCC risk after achieving SVR for his hepatitis C? [1]

A: "Successful HCV eradication with DAAs substantially reduces but does NOT eliminate the HCC risk, because the cirrhosis — the architectural distortion, regenerative nodules, and genomic field defect — persists after the virus is cleared [1]. The residual annual HCC risk in a cirrhotic patient post-SVR is approximately 0.5 to 1 percent, compared with 2 to 4 percent in untreated HCV cirrhosis. This is why surveillance continues for life regardless of SVR. Stopping surveillance after SVR is one of the most common and dangerous errors in hepatology practice."

Q: What if this patient had been found to have portal vein tumour thrombus — how would that change the management? [1]

A: "Portal vein tumour thrombus upstages the patient from BCLC A to BCLC C (advanced), because vascular invasion is a defining feature of BCLC C. The treatment allocation shifts from curative therapy to systemic therapy. TACE becomes contraindicated because it requires a patent portal vein — embolising the hepatic artery when the portal vein is occluded risks total hepatic ischaemia. The first-line systemic therapy would be atezolizumab plus bevacizumab (after an upper GI endoscopy to screen for varices, because bevacizumab can precipitate catastrophic bleeding from untreated varices), with sorafenib or lenvatinib as single-agent TKI alternatives. The prognosis changes from a curable early cancer to an advanced cancer with a median survival of approximately 19 months on the best systemic therapy [4][5]."

Q: What surveillance does he need, and why does the interval matter? [1]

A: "He needs six-monthly liver ultrasound plus serum AFP, for life. The six-monthly interval is based on HCC tumour doubling times — a six-monthly interval detects most tumours before they exceed curative thresholds. The Singal 2014 meta-analysis of 47 studies and over 15 000 cirrhotic patients confirmed that surveillance improves early-stage detection (OR 2.08), receipt of curative treatment (OR 2.24), and overall survival (OR 1.90), with the benefit persisting after adjustment for lead-time bias [3]. Annual surveillance would miss tumours that grow rapidly between scans; three-monthly surveillance would be excessive and resource-intensive without a proven additional benefit. After curative treatment, the surveillance continues because the cirrhotic liver (or the transplant graft) can produce new tumours."

Q: What would you do differently if his liver function were Child-Pugh C? [1]

A: "Child-Pugh C cirrhosis with HCC changes the BCLC stage to D (terminal) if the patient is NOT a transplant candidate — the management shifts to best supportive care, because active anti-cancer treatment (resection, TACE, systemic therapy) carries prohibitive harm in a liver with decompensated function. However, if the patient IS within transplant criteria (Milan criteria for the tumour, and otherwise a suitable transplant candidate), a Child-Pugh C patient with HCC may be an urgent transplant candidate — transplant treats both the tumour and the decompensated liver. So Child-Pugh C does not automatically mean BCLC D — it depends on whether transplant is feasible. The distinction is critical and is a common exam trap [2]."

Communication and shared decision-making

"I would explain to Mr M that his surveillance programme has done exactly what it was designed to do — detect a liver cancer at an early, curable stage. This is the best-case scenario for an HCC diagnosis. I would explain that the cancer arose from his cirrhosis, which persists despite his hepatitis C being cured, and that the cirrhosis will need lifelong monitoring. I would lay out the three curative options — resection, ablation, and transplant — and explain that the decision depends on a measurement of his portal pressure that we will arrange. I would be honest that a transplant is a major undertaking with lifelong immunosuppression and a waiting period for a donor organ, but it offers the best chance of long-term cure because it treats both the tumour and the underlying liver disease. I would address his anxiety about surgery, involve his family in the discussions, and connect him with a patient who has been through a similar journey. I would document the shared decisions and review them as the treatment plan unfolds." [1]

Outcome and follow-up

Mr M is discussed at the hepatobiliary MDT. His HVPG is measured at 12 mmHg, confirming clinically significant portal hypertension. Resection is deemed high-risk for post-hepatectomy liver failure. Because he is within Milan criteria and has a suitable cardiac and renal assessment, he is listed for liver transplant. While awaiting a donor organ, he receives TACE as bridging therapy to prevent tumour progression beyond Milan criteria. His TACE is uncomplicated, with post-embolisation syndrome (fever, pain) managed with simple analgesia. His AFP falls from 180 to 45 ng/mL after TACE, indicating a treatment response. [1]

He is started on carvedilol 6.25 mg daily for primary prophylaxis of variceal bleeding. His diabetes and hypertension are optimised. A dietitian addresses his mild sarcopenia with a high-protein, nocturnal feeding strategy. He and his family receive counselling and are connected with a liver transplant support group. [1]

Four months after listing, a deceased donor liver becomes available. Mr M undergoes orthotopic liver transplant without complication. The explant histology confirms a moderately differentiated HCC, 4.2 cm, with no microvascular invasion — all margins clear. He is started on tacrolimus and mycophenolate for immunosuppression, with a plan to transition to an mTOR inhibitor (sirolimus) at 3 months post-transplant, given emerging evidence that mTOR inhibitors may reduce HCC recurrence risk. [1]

Post-transplant surveillance begins: six-monthly liver ultrasound plus AFP for HCC recurrence, annual chest CT for the first two years (lung is the commonest recurrence site), and standard graft surveillance. At one year post-transplant, Mr M is well, his AFP is normal, and there is no evidence of recurrence. His immunosuppression is stable on sirolimus monotherapy. He remains under lifelong hepatology and transplant follow-up. [1]